Compare Gilead Sciences, Inc. (GILD) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares MSCI China ETF — how do they compare? Gilead Sciences, Inc. trades at $135.94 (market cap $163.51B), while iShares MSCI China ETF trades at $54.1. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MSCI China ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| GILD | MCHI | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $66.99 |
52-Week Low | $108.22 | $50.48 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MCHI trades at $54.10, up 1.63% with a bullish technical signal from moving averages. The stock shows strong momentum with ADX indicating a strong trend, though RSI levels suggest potential overbought conditions. Recent news highlights China's AI and manufacturing resurgence, with exports growing 19.4% year-over-year in May 2026 (Reuters, 2026-06-08).
The outlook remains cautiously optimistic given China's $295 billion AI investment plan (Bloomberg, 2026-06-09) and factory rebound. However, risks include US-China trade tensions and concerns about Chinese equities being value traps. Analyst sentiment is mixed with some maintaining sell ratings due to structural headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
